Difference between revisions of "Team:Tongji China/Model"
| Line 22: | Line 22: | ||
</div> | </div> | ||
<div class="linkOfPicture"> | <div class="linkOfPicture"> | ||
| − | + | <a href="/Team:Tongji_China/Programme" class="test_a"><img src="https://static.igem.org/mediawiki/2018/f/fb/T--Tongji_China--picture-Dry_Lab-Overview-1_Programming.png" width="32%" style="margin-right:75px; margin-left:75px;></a> | |
| − | <a href="/Team:Tongji_China/Modeling" class="test_a"><img src="https://static.igem.org/mediawiki/2018/1/1b/T--Tongji_China--picture-Dry_Lab-Overview-2_Modeling.png" width="32%" style="margin-left:75px; margin-right:75px;></a | + | <a href="/Team:Tongji_China/Modeling" class="test_a"><img src="https://static.igem.org/mediawiki/2018/1/1b/T--Tongji_China--picture-Dry_Lab-Overview-2_Modeling.png" width="32%" style="margin-left:75px; margin-right:75px;></a> |
</div> | </div> | ||
</div> | </div> | ||
Revision as of 14:21, 11 October 2018
Dry Lab
Overview
With information of colorectal cancer mutations from the TCGA database, we use “mutated” CDSs centered by the mutation sites and use an 8~14aa long slide window to cut the amino acid sequences around the mutated site. Then we put these amino sequences into NetMHC and predict their immunogenicity. We choose strong biding peptides for later use.
